

CURRICULUM VITAE

Howard (Jack) West, MD

Executive Director, Employer Strategies
Associate Clinical Professor
4900 Rivergrade Road, #2126
Irwindale, CA 91706
Tel: 626-218-6144
Cell: 206-898-4515
e-mail: hwest@coh.org
Date Prepared: March 14, 2019

I. EDUCATION

University Princeton University, Princeton, NJ; AB (*summa cum laude*) in Psychology (Physiologic), 1990

Graduate School University of Cambridge, Cambridge, UK; MPhil in Experimental Biology, 1992

Medical School Harvard Medical School, Boston, MA; MD (*magna cum laude*), 1996

II. POST GRADUATE EDUCATION AND TRAINING

Internship Brigham & Women's Hospital (Internal Medicine), Boston, MA, 6/96 – 6/97

Residency Brigham & Women's Hospital (Internal Medicine), Boston, MA, 6/97 – 6/98 (clinical investigator track)

Fellowship Fred Hutchinson Cancer Research Center/Univ of Washington (Medical Oncology), Seattle, WA, 10/98 – 10/2002

CERTIFICATIONS

- ABIM Internal Medicine, 2000 (lapsed)
- ABIM Medical Oncology, 2002, renewed 2012 (active)

MEDICAL LICENSURES (many obtained to facilitate inter-state telemedicine consultations)

- California, Lic. #C55294, issued 2012 (active)
- Washington, Lic. #34681, issued 1998 (active)
- Arizona, Lic. #46173, issued 2012 (inactive)
- Florida, Lic. #P3097, issued 2012 (inactive)
- Hawaii, Lic. #16554, issued 2012 (inactive)
- Illinois, Lic. #036130103, issued 2012 (inactive)
- Massachusetts, Lic. #156940 (inactive)
- Pennsylvania, Lic. #MD445767 (inactive)
- Texas, Lic. #ME113236 (inactive)
- Virginia, Lic. #0101251883 (inactive)

III. PROFESSIONAL EXPERIENCE, POSITIONS & EMPLOYMENT

- 6/98 – 9/98 New England Sinai Hospital & Rehabilitation Center; Stoughton, MA
Moonlight/Provisional Internal Medicine Staff
- 6/98 – 9/98 Beverly Hospital; Beverly, MA
Moonlight/Provisional Internal Medicine Staff
- 6/98 – 9/98 Deaconess Waltham Hospital; Waltham, MA,
Moonlight/Provisional Internal Medicine Staff
- 9/00 – 8/01 Stevens Hospital (now Swedish Hospital, Edmonds); Edmonds, WA
Moonlight/Provisional Internal Medicine Staff (Medical Oncology)
- 10/01 – 10/02 University of Washington, Seattle, WA
Acting Instructor, Medical Oncology
- 12/02 – 3/19 Swedish Medical Center/Providence Health Care, Seattle, WA
Medical Oncologist, Medical Director, Thoracic Oncology Program

Academic Appointments

Instructor, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, 2/02-12/02

Clinical Administrative Appointments

Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA, 2002
Chair, Outreach/Education/Telemedicine Workgroup, Providence System, Seattle, WA, 2016

Other Professional Activities

Founder & President, Global Resource for Advancing Cancer Education (GRACE), 501c3 non-profit providing free, expert information on current & best treatments to cancer patients and caregivers, 2007 – present

Section Editor (2017 – present) & author (2011 – present), multiple portions of lung cancer content

JAMA Oncology Founding Web Editor, 2014 – present

Medscape Columnist (monthly) & ASCO/World Conference on Lung Cancer Correspondent, 2014 – present

Founder & Moderator, Lung Cancer Expert Summit, 2017, 2018, 2019

IV. HONORS AND AWARDS

- 1989 Howard Crosby Warren Junior Prize in Psychology, Princeton University (best student in dept.)
- 1990 Howard Crosby Warren Senior Prize in Psychology, Princeton University (best student in dept.)
Phi Beta Kappa Society, Princeton University (overall academic achievement)
Sigma Xi Society, Princeton University (scientific achievement)
Daniel M. Sachs '60 Scholarship, Princeton University, for “character, commitment, & intelligence”
Fulbright Scholarship to UK for overseas research
Overseas Research Grant, UK government support (graduate research grant)
- 1992 Albert Schweitzer Society Urban Fellowship (supporting urban community medical care projects)
Hartford Society Scholarship in Gerontology (support for health care projects for elderly patients)
- 1993 Howard Hughes Medical Institute Student Fellowship (supporting year of clinical/translational research at Massachusetts General Hospital)
- 1994-96 Howard Hughes Medical Institute Continued Support Fellowship (additional funding for clinical training and research)
- 2001 Southwest Oncology Group Young Investigator Training Program (developed clinical trial, later executed, presented, and published)
ASCO/AACR Workshop in Clinical Cancer Research, Vail, CO (further developed clinical trial, later executed, presented, and published)
- 2002 GSK National Medical Oncology Fellows' Forum, Oral Presentation of original research (finalist)

- 2002-04 Innovators in Lung Cancer, International Program training in leadership in thoracic oncology (yearly summit, annual program x 3 years)
- 2012 Swedish Physician Leadership Program, training for cultivating leadership skills among faculty

V. CLINICAL ACTIVITIES

- 6/98 – 9/98 New England Sinai Hospital & Rehabilitation Center; Stoughton, MA; Beverly Hospital; Beverly, MA; Deaconess Waltham Hospital; Waltham, MA
Moonlight/Provisional Internal Medicine Staff, covering admissions, urgent care for inpatients on overnight shift, generally 1-4 admissions/shift
- 9/00 – 8/01 Stevens Hospital (now Swedish Hospital, Edmonds); Edmonds, WA
Moonlight/Provisional Internal Medicine Staff (Medical Oncology), covering weekend rounding on inpatients, admissions, consults, and calls from outpatients; 4-15 inpatients, 1-3 admissions per weekend
- 12/02 – 1/19 Swedish Cancer Institute, Seattle, WA;
Medical Oncologist; Medical Director, Thoracic Oncology Program
75% clinical care (approximately 3.5 days/week); 15-20 patients per day seen solo (no APC or fellow support), approx. 70% thoracic, 30% genitourinary cancers; Leadership of clinical and research programs in thoracic oncology, seeing >75% of thoracic oncology patients, including outpatient referrals and inpatient consults, needing clinical care at largest private oncology program in the Pacific Northwest. Available/on call for patients Monday through Friday; weekend call every 8-14 weekends, covering inpatient oncology service typically with 15-30 inpatients, along with covering hematology/oncology consults and outpatient calls.

VI. SERVICE TO INSTITUTION

Administrative Service

Member, Patient Care Quality Review Committee, Swedish Medical Center, 2003 – 2008

Member, Clinical Research Steering Committee, Swedish Medical Center, 2003 – present

Co-Chair, Swedish Prostate Cancer Symposium Planning Committee, 2004

Member, Institutional Review Board, Cancer Research and Biostatistics (CRAB), 2004 – 2013

Member, Swedish Medical Center Physician Leadership Forum, 2013 – present

Co-Chair, Swedish Lung Cancer Symposium Planning Committee, 2014

Member, Swedish Personalized Medicine Research Program Scientific Committee, 2017 – present

Member, Quality of Cancer Care Committee, 2017 – present

Teaching Service

- Rotation of University of Washington Medical Oncology Fellows through clinics, 2003-2011, primarily in “shadowing” role, changing on monthly basis

Other Research Mentoring Activities/Committees

- Launching Global Resource for Advancing Cancer Education (GRACE) Patient Education Ambassador training program, 2019

VII. SERVICE TO PROFESSION

Professional Organizations

National/International ASCO Scientific Committee, Lung Cancer Track, 2006-2008 and 2011-2014
Chair, ASCO Metastatic Non-Small Cell Lung Cancer Committee, 2013
NIH Thoracic Malignancies Steering Committee, 2013 – 2016
International Association for the Study of Lung Cancer, Educational/Conference
Planning Committee, 2015, 2018
ACCC ALK-Positive NSCLC Advisory Committee, 2016 – present

Regional/Local Washington State Medical Oncology Society, Board of Directors, 2006 – 2008

Editorships Web Editor, JAMA Oncology, 2014 – present

Editorial Boards Journal of Clinical Oncology, editorial board, 2012 – 2015
Clinical Lung Cancer, editorial board, 2013 – present
Oncology Live, editorial board, 2013 – present
www.cancer.net (ASCO patient education), editorial board, 2014 - present

Journal Reviews Cancer, Cancer Investigation, Cancer Letters, Clinical Cancer Research, Community
Oncology, Expert Opinion in Biological Therapy, Journal of Clinical Oncology,
Journal of Thoracic Oncology, Lancet, Lancet Oncology, Nature Clinical Practice
Oncology, Nature Reviews, Oncologist, Oncology

Grant Reviews Free to Breathe (lung cancer nonprofit), Lung Cancer Research Grant Review
Committee, 2016

Community Service Speaker, Lung Cancer Connection Annual Meeting, 2011
#LCSM (Lung Cancer Social Media) online twitter chat founding moderator,
continued moderation 2016-2018
Speaker, LUNG FORCE, American Lung Association, 2016
Speaker, LUNGeivity fundraiser, 2016-2018
Speaker, LUNGeivity Patient HOPE Summit, 2017
International Association for the Study of Lung Cancer, Patient Advocacy
Committee, 2011 – 2012, 2016 – 2017
Speaker, Bonnie J. Addario Lung Cancer Foundation Living Room, 4/2018

Other: President, Global Resource for Advancing Cancer Education, cancer education non-
profit providing free expert commentary for patients and caregivers
Author, UpToDate, Non-Surgical Management of Early Stage NSCLC, Systemic
Therapy for Early Stage NSCLC, Management of Oligometastatic NSCLC,
Immunotherapy in Advanced NSCLC, Management of Brain Metastases in
NSCLC, Management of Pericardial Effusions

Symposia

- Bronchioloalveolar carcinoma (BAC): EGFR-based therapy and beyond; Winter Lung Cancer Conference, Miami, FL, 3/05
- Bronchioloalveolar carcinoma (BAC): Predictive factors of response to EGFR TK inhibitors. Atlanta Lung Cancer Symposium, Atlanta, GA, 2005
- Options for stage IIIA N2 NSCLC: Surgical and non—surgical options. Challenging Cases in Lung Cancer. Miami, FL, 7/07
- Designs for targeted therapy trials: New problems, new potential, and new paradigms. IASLC Clinical Trials and Biostatistics Workshop, World Conference on Lung Cancer, Seoul, Korea, 9/07
- Unresectable locally advanced NSCLC: Improving survival with old and new tools. Challenging Cases in Emerging Data, Chicago, IL, 9/07
- Advanced NSCLC: New targets and new tools. Challenging Cases in Emerging Data, San Francisco, CA, 9/07
- Recent developments in managing advanced NSCLC. Challenging Cases in Emerging Data, Scottsdale, AZ, 9/08
- Adjuvant chemotherapy for resected non-small cell lung cancer. Challenging cases in breast and lung cancer. San Diego, CA, 3/10
- Molecular markers and testing strategies in advanced non-small cell lung cancer, Challenging Cases in Breast and Lung Cancer, Orlando, FL, 5/10
- Adjuvant chemotherapy for resected non-small cell lung cancer. Challenging cases in breast and lung cancer. Las Vegas, NV, 9/10
- Molecular markers and testing strategies in advanced non-small cell lung cancer, Challenging Cases in Breast and Lung Cancer, Las Vegas, NV, 4/12
- Improving resistance to EGFR inhibition: The cornerstone remains targeted therapy. Great Debates & Updates in Thoracic Malignancies, San Francisco, CA, 5/12
- Optimal first line therapy for advanced NSCLC patients with an EGFR mutation, Challenging Cases in Oncology, Chicago, IL, 8/12
- Transitioning survival from months to years in advanced non-small cell lung cancer (NSCLC), Annual Oncology Symposium: Thoracic Malignancies, Seattle, WA, 5/2014
- The third party in the exam room: Dr. Google and online patient communities: Annual Oncology Symposium: Thoracic Malignancies, Seattle, WA, 5/2014
- Necitumumab should not be standard of care treatment in advanced NSCLC despite a statistically significant improvement in OS. Personalized Therapies and Best Clinical Practices for Lung Cancer, Los Angeles, 10/14
- Immune checkpoint inhibitors in NSCLC: first line or second line? Personalized Therapies and Best Clinical Practices for Lung Cancer, Los Angeles, 10/14
- Social Media as a Tool for Physician and Patient Education. Pre-conference symposium, ASCO Annual Conference; Chicago, IL, 5/15
- First line treatment of choice for EGFR del 19 mutation-positive advanced NSCLC is afatinib. Great Debates & Updates in Thoracic Malignancies; La Jolla, CA, 7/15
- Next generation sequencing should be a part of the default workup for advanced NSCLC patients. Great Debates and Updates in Thoracic Malignancies; La Jolla, CA, 7/15
- Treatment options for EGFR T790M-negative acquired resistance. GRACE Targeted Therapies for Driver Mutations Patient Forum; San Francisco, CA, 10/15
- Broad molecular testing for advanced NSCLC; Personalized Medicine in Lung Cancer Conference, San Francisco, CA, 10/15

- Is the optimal therapy for advanced NSCLC with an activating mutation a combination?; Personalized Medicine in Lung Cancer Conference, San Francisco, CA, 10/15
- Treatment of EGFR T790M-positive acquired resistance in advanced NSCLC; EGFR Therapies in NSCLC 2.0 (ASCO CME symposium), Chicago, IL, 6/16
- Are there differences among first- and second-generation EGFR-directed therapies? Yes. EGFR Therapies in NSCLC 2.0 (ASCO CME symposium), Chicago, IL, 6/16
- Treatment of EGFR mutation-positive acquired resistance in advanced NSCLC: T790M-positive or T790M-negative; GRACE Targeted Therapies for Driver Mutations Patient Forum; Denver, CO, 8/16
- From evidence to everyday practice: Key influences on how oncologists treat patients; Business of Cancer, Dallas, TX, 10/16
- Adding value for investigators and community-based oncologists: A changing world with new opportunities; Business of Cancer, Dallas, TX, 10/16
- EGFR mutation-positive lung cancers: Choosing the best upfront treatment. New York Lung Cancer Symposium, New York, NY, 11/16
- Best practices for managing advanced EGFR mutation-positive NSCLC after disease progression. Changing Treatment Paradigm After Progression in Advanced EGFR Mutation-Positive NSCLC (World Conference on Lung Cancer CME symposium); Vienna, Austria, 12/16
- Selective immune checkpoint inhibitor therapy in patients with high PD-L1 expression; Immune Therapies for Cancer Master Class, Dallas, TX, 3/17
- Evolving strategies for previously treated advanced NSCLC. Challenging Cases in Oncology, San Francisco, 5/17
- Immune checkpoint inhibitors in first-line therapy for advanced NSCLC; Immune Checkpoint Inhibitors in NSCLC Care: Experts Address Clinical Challenges to Clarify Optimal Use (ASCO CME symposium), Chicago, IL, 6/17
- Sequencing decisions for patients with ALK+ NSCLC beyond disease progression. ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs along the Disease Continuum (ASCO CME symposium), Chicago, IL 6/17
- Sifting through the wreckage: Assessing cancer information from sources of varying quality; GRACE Targeted Therapies for Driver Mutations Patient Forum; Cleveland, OH, 9/17
- Treatment of EGFR mutation-positive acquired resistance in advanced NSCLC: T790M-positive or T790M-negative; GRACE Targeted Therapies for Driver Mutations Patient Forum; Cleveland, OH, 9/17
- For which NSCLC patients should immunotherapy be a lower priority?; Personalized Therapies in Lung Cancer Symposium; Los Angeles, CA, 10/2017
- Treatment options for ALK+ NSCLC with acquired resistance to prior ALK inhibitor therapy: What now? Personalized therapies in lung cancer. Los Angeles, CA, 10/17
- Proceed with caution: Immunotherapy in patients with prior immune-related adverse events on autoimmune disease; Personalized Therapies in Lung Cancer Symposium; Los Angeles, CA, 10/17
- Treatment options for patients with ALK+ NSCLC that has progressed on a prior ALK inhibitor; Los Angeles, CA, 10/17
- Selecting first line and second line therapy in the setting of EGFR mutation-positive NSCLC; HOPA Annual Conference, Denver, CO, 3/18
- The evolving treatment landscape in locally advanced and metastatic NSCLC: Challenging Cases in Medical Oncology, San Diego, CA, 3/18
- Immunotherapy for stage I-III lung cancer: Can we translate efficacy into more cures?

Immune Checkpoint Blockade in NSCLC: Expert Perspectives on Current Standards and the Next Frontier (ASCO CME Symposium), Chicago, IL, 6/2018
Immunotherapy for the treatment of lung cancer. SITC Advances in Cancer Immunotherapy Symposium. Seattle, WA, 11/18
Immunotherapy in first-line NSCLC. CME symposium, How Immunotherapy is Revolutionizing Lung Cancer Care. Canadian Lung Cancer Conference, Vancouver, BC, Canada, 2/2019

Sessions Chaired

Pacific Northwest Thoracic Oncology Symposium, Seattle, WA (CME Conference), 2004
Multidisciplinary Interactive Thoracic Oncology Conference, Seattle, WA;
Annual CME Conference, 2005 – 2009
Emerging Trends in Oncology, Seattle, WA, 7/2006
Current Trends in Lung Cancer and Head & Neck Cancer, Seattle, WA, 3/2009
GRACE Patient Forum on Acquired Resistance to Targeted Therapies in Lung Cancer, Boston, MA, 9/14
GRACE Patient Forum on Immunotherapy for Melanoma, Lung, and Renal Cancers, Chicago, IL, 10/14
Clinical Care Options, Integrating the New Paradigm of Immuno-Oncology into NSCLC Management (CME: >1000 attendees), Denver, CO, 9/15
GRACE Patient Forum on Acquired Resistance to Targeted Therapies in Lung Cancer, San Francisco, CA, 11/15
Immunotherapies for Advanced NSCLC: Current State of the Field: Atlanta Cancer Symposium, Atlanta, GA, 8/2016
Biomedical Learning Institute, Personalized Therapies in Lung Cancer, San Francisco, CA, 10/16
Biomedical Learning Institute, Lung Cancer Master Class, Dallas, TX, 3/17
OnLive State of the Science, NSCLC, Seattle, WA, 4/17
Immune Checkpoint Inhibitors in NSCLC Care: Experts Address Clinical Challenges to Clarify Optimal Use, ASCO CME symposium, Chicago, IL, 6/17
Triptych Health Partners, Lung Cancer Expert Summit, Washington, DC, 6/17
Clinical Care Options, Immune Checkpoint Blockade in NSCLC: Expert Perspectives on Current Standards and the Next Frontier (ASCO CME symposium) Chicago, IL, 6/18
Triptych Health Partners, Lung Cancer Expert Summit, Dallas, TX 6/18
Controversies in first-line management of EGFR mutant NSCLC: Presence of CNS metastases. EGFR Mutant NSCLC: Evolving Treatment Paradigms and Game Changers for Current and Future Front-Line Care (World Conference on Lung Cancer CME symposium), Toronto, ON, Canada, 9/18
Biomedical Learning Institute, Lung Cancer Master Class, Dallas, TX, 10/18
Locally advanced and metastatic NSCLC Immersion Summit, Seattle, WA, 1/19

Research Committees

ABOUND trials Steering Committee, 2015-2018
RADIANCE Trial Steering Committee, 2017-2018

VIII. PUBLICATIONS

Publications (peer-reviewed): 25 total published, 1 in revision

1. **West HL**, Mark GP, & Hoebel, BG. Effects of conditioned taste aversion on extracellular serotonin in the lateral hypothalamus and hippocampus of freely moving rats. *Brain Res* 556: 95-100, 1991.
2. Marston HM, **West HL**, Wilkinson, LJ, Everitt BJ, & Robbins TW. Effects of cytotoxic lesions of the medial septum and vertical limb nucleus of the diagonal band of Broca on conditional visual discrimination: Relationship between discrimination performance and choline acetyltransferase activity in the cingulate cortex. *J Neurosci*, 14:2009-2019, 1994.
3. **West HL**, Rebeck GW, & Hyman BT. Frequency of the apolipoprotein E e2 allele is diminished in sporadic Alzheimer's disease. *Neurosci Lett* 175: 46-48, 1994.
4. Rebeck GW, Perls TP, **West HL**, Sodhi P, Lipsitz LA, & Hyman BT. Reduced apolipoprotein e4 allele frequency in the oldest old Alzheimer's patients and cognitively normal patients. *Neurol*, 44: 1513-1516, 1994.
5. Hyman BT, **West HL**, Rebeck GW, Lai F, & Mann DMA. Neuropathological changes in Down syndrome hippocampal formation: effect of age and apolipoprotein E genotype. *Arch Neurol* 52: 373-378, 1995.
6. Hyman BT, **West HL**, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, & Stanley HE. Quantitative analysis of senile plaques in Alzheimer's disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21(Down syndrome). *Proc Nat Acad Sci USA* 92: 3586-3590, 1995.
7. Gomez-Isla T, **West HL**, Rebeck GW, Harr SD, Growden JH, Locasio JT, Perls T, Lipsitz, LA, & Hyman BT. Clinical and pathological correlates of apolipoprotein E e4 in Alzheimer's disease. *Ann Neurol* 39: 62-70, 1996.
8. Gomez-Isla T, Hollister R, **West H**, Mui S, Growdon JH, Petersen RC, Parisi JE, & Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann Neurol* 41: 17-24, 1997.
9. Gandara DR, **West H**, Chansky K, Davies AM, Lau DHM, Crowley J, Gumerlock PH, & Franklin W. Bronchioloalveolar carcinoma: A model for investigating the biology of EGFR Inhibition. *Clin Cancer Res* 10: 4205s-4209s, 2004.
10. **West HL**, Crowley JJ, Vance RB, Franklin WA, Livingston RB, Dakhil SR, Giguere JK, Rivkin SE, Kraut M, Chansky K, & Gandara DR. Advanced bronchioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714). *Ann Oncol* 16: 1076-1080, 2005.
11. Hirsch FR, Varella-Garcia M, McCoy J, **West H**, Xavier, AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, & Gandara DR. Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). *J Clin Oncol* 2005; 23: 6838-6845, 2005.
12. **West HL**, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, & Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. *J Clin Oncol* 24: 1807-1813, 2006.
13. Nemunaitis J, Meyers T, Senzer N, Cunningham C, **West H**, Vallieres E, Anthhony S, Vukelja S, Berman, B, Tully H, Pappen BV, Sarmiento S, Arzaga R, Duniho S, Engardt S, Meagher M, & Cheever

- MA. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. *Molec Ther*, 13: 1185-91, 2006.
14. Hirsch F, Varella-Garcia M, Capuzzo F, McCoy J, Bemis L, Xamier A, Dziadziuszko R, Gumerlock P, Chansky K, **West H**, Gazdar A, Crino L, Gandara D, Franklin W, & Bunn P, Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. *Ann Oncol* 18:752-760, 2007.
 15. Chen G, Huynh H, Fehrenbacher L, **West H**, Lara, PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, & Lau D. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. *J Clin Oncol* 27: 1401 – 1404, 2009.
 16. **West HL**, Wakelee HA, Perry MC, Belt RJ, Chen R, & Obasaju C. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small cell lung cancer: A phase II clinical trial. *Ann Oncol* 20: 850 -856, 2009.
 17. Green, MR. **West H**, & Socinski, MA. Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer. *J Thor Oncol* 4: 983-987, 2009.
 18. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, **West HL**, Azada MC, Morcos PN, Lee R-M, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, & SH Ou. Safety and efficacy of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. *Lancet Oncol* 15: 1119-1128, 2014.
 19. Camidge DR, Berge EM, Doebele RC, Ballas M, Jahan T, Haigentz M, Hoffman D, Spicer J, **West H**, Lee P, Yang L, Joshi A, Yurasov S, & Mita A. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small cell lung cancer. *J Thorac Oncol* 9: 1532-1539, 2014.
 20. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, **West H**, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Blas B, Puig O, Henschel V, Ou S-HO. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicenter, phase 2 trial. *Lancet Oncol* 17: 234-2242, 2016.
 21. Wilshire CL, Louie BE, Horton MP, Castiglioni M, Aye RW, Farivar AS, **West HL**, Gorden JA, & Vallières E. Comparison of outcomes for patients with lepidic pulmonary adenocarcinoma defined by 2 staging systems: A North American experience. *J Thorac Cardiovasc Surg* 151: 1561-1568, 2016.
 22. Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, Hansen KH, Kim S-W, Huber RM, **West HL**, Groen JM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz Arez Rodriguez LG, Smit, EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized multicenter phase II trial. *J Clin Oncol* 35: 2490-2498, 2017.
 23. Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, **West H**, Ko A, Ong JT, Trunova N, Gridelli C. Nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. *Lung Cancer: Targ Ther* 8: 207-216, 2017.
 24. **West H**, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, & Gandara DR. Paired phase II studies of erlotinib/ bevacizumab in advanced bronchioloalveolar carcinoma or in never-smokers with advanced non-small-cell lung cancer (NSCLC): SWOG S0635 and S0636 trials. *Clin Lung Cancer* 19: 84-92, 2018.

25. Camidge DR, Kim D-W, Tiseo M, Langer CJ, Ahn M-J, Shaw AT, Huber RM, Hochmair MJ, Lee, DH, Bazhenova LA, Gold KA, Ou S-HI, **West HL**, Reichmann W, Haney J, Clackson T, Kerstein D, & Gettinger SN. Exploratory analysis of brigatinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. *J Clin Oncol* 36: 2693-2701, 2018
26. **West H**, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp H-G, Daniel D, McCune S, Tekhail T, Zer A, Reinsmuth N, Sadiz A, Sandler A, Lin W, Lohmann TO, Archer V, Wang L, Kowanetz M, & Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel, compared with carboplatin plus nab-paclitaxel for first line treatment of metastatic non-squamous NSCLC (IMpower130): a phase 3 study. *Lancet Oncol*, in press.

Publications (review articles): 21 Total

1. Hoebel BG, Mark GP, & **West HL**. Conditioned neurotransmitter release. Symposium on Regulation of Food Intake, Metabolism, and Energy Balance 4: 36-42, 1990.
2. Hernandez L, Parada M, Baptista T, Schwartz D, **West HL**, Mark GP, & Hoebel BG. Hypothalamic serotonin in treatments for feeding disorders and depression as studied by brain microdialysis. *J Clin Psych* 52 Suppl.: 32-40, 1991.
3. Hyman BT, Gomez-Isla T, **West H**, Briggs M, Chung H, Growden JH, & Rebeck GW. Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease: Window on molecular epidemiology. *Ann New York Acad Sci* 777: 158-165, 1996.
4. Hyman BT, Hedley-Whyte ET, Rebeck GW, Vonsattel JP, **West HL**, & Growdon JH. Apolipoprotein E4/4 in a neuropathologically normal very elderly individual. *Archives of Neurology*, 1996; 53: 215.
5. Hyman BT, Gomez-Isla T, Rebeck GW, Briggs M, Chung H, **West HL**, Greenberg S, Mui S, Nichols S, Wallace R, & Growdon JH. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. *Ann New York Acad of Sci* 802: 1-5, 1996.
6. Disis ML, **West HL**, & Schiffman K. Cancer vaccines for the treatment and prevention of non-small cell lung cancer. *Clin Lung Cancer* 1: 294-301, 2000.
7. Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, & **West HL**. Myalgias & arthralgias associated with paclitaxel: A review of incidence and management. *Oncol* 17: 271-277, 2003.
8. Gandara DR, **West H**, Albain KS, Werner-Wasik M, Crowley J, & Choy H. Defining the role of radiation therapy in Stage III non-small cell lung cancer: Rationale and design of a new intergroup study. American Society of Clinical Oncology 40th Annual Meeting Educational Book. pp. 458-462, 2004.
9. **West H** & Albain KS. Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer. *Semin Oncol* 32: 284-292, 2005.
10. **West H**. Emerging approaches to advanced bronchioloalveolar carcinoma. *Curr Treat Opt Oncol* 7: 69-76, 2006.
11. Kris MG, Giaccone G, Davies A, Fukuoka M, Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Van Meerbeeck JP, & **West H**. Systemic therapy of bronchioloalveolar carcinoma: results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. *J Thorac Oncol* 1: S32-S36, 2006.
12. **West, H**. Gefitinib in advanced bronchioloalveolar carcinoma (BAC): A case study and review of clinical research on EGFR tyrosine kinase inhibitor therapy for BAC. *Am J Heme/Oncol* 5 (suppl 10): 9-12, 2006.

13. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, **West H**, & Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. *J Thor Oncol* 3: 545-555, 2008.
14. Garfield DH, Cadranel J, & **West HL**. Bronchioloalveolar carcinoma: The case for two diseases. *Clinical Lung Cancer* 9: 24-29, 2008.
15. **West H**, Harpole D, & Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. *CHEST* 136; 1112-1118, 2009.
16. **West H**, Lilenbaum R, Harpole D, et al. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. *J Thor Oncol* 4 (suppl 2): S1029-1039, 2009.
17. **West H**. The evolving role of targeted therapy in early stage and locally advanced non-small cell lung cancer. *Curr Oncol Rep* 13: 280-289, 2011.
18. West H, deBronkard D, & Demetri GD. A New Model: Physician-Patient Collaboration in Online Communities and the Clinical Practice of Oncology. *ASCO Ed Book* pp. 443-448, 2012.
19. **West H**, Oxnard GR, & Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer. New strategies and new agents. *ASCO Ed Book* pp. 272-278, 2013.
20. **West H**. Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity. *Clin Adv Hem Onc* 12: 593-600, 2014.
21. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, **West H**, Whitlock S, & Somerfield MR. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the American Pathologists/ International Society for the Study of Lung Cancer/Association of Molecular Pathologists guideline. *J Clin Oncol* 32: 3673-3679, 2014.

Editorials and Letters: 41 Total

1. **West H**. EGFR inhibitors fight BAC. *Signal*; 1: 18-20, 2005.
2. **West H** & Garfield DH. Bronchioloalveolar carcinoma: not as easy as “BAC”. *J Thor Oncol* 4: 1047-1048, 2009.
3. **West H**. The role for surgery in stage III non–small-cell lung cancer: Can we reliably select the right patients? *Clin Lung Cancer* 10: 314-316, 2009.
4. Stinchcombe TE & **West HL**. Maintenance therapy in non-small-cell lung cancer. *Lancet* 374: 1398-1400, 2009.
5. **West H**. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: Incremental benefit, debatable value. *J Clin Oncol* 29: 1095-1098, 2011.
6. **West H**, & Camidge DR. Have mutation, will travel: Utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology. *J Thor Oncol* 7: 482-484, 2012.
7. **West H**. Practicing in partnership with Dr. Google: The growing effect of social media in oncology practice and research. *Oncologist* 18: 780-782, 2013.
8. **West H**. Patients with advanced non-small-cell lung cancer and marginal performance status: Walking the tight rope toward improved survival. *J Clin Oncol* 31: 2841-2843, 2013.
9. **West H**. Afatinib for advanced mutation NSCLC: New hope or new Coke? *J Commun Supp Oncol* 12: 115-117, 2014.
10. **West H**. The failure of figitumumab: the danger of taking shortcuts in drug development. *Ann Oncol* 26: 447-448, 2015/

11. **West H.** Individualizing adjuvant therapy for early stage non-small cell lung cancer: we see the destination, but we don't yet know the route. *J Thorac Dis* 7: 235-237; 2015.
12. **West H.** Immune checkpoint inhibitors. *JAMA Oncol* 1: 115, 2015
13. **West H.** Malignant pleural effusions. *JAMA Oncol* 1: 260, 2015.
14. **West H.** Circulating tumor cells. *JAMA Oncol* 1: 394, 2015.
15. **West H & Jin J.** Neoadjuvant therapy. *JAMA Oncol* 1: 550, 2015.
16. **West H & Jin J.** Adjuvant therapy. *JAMA Oncol* 1: 698, 2015.
17. **West H & Jin J.** The evolution of a cancer. *JAMA Onc* 1: 850, 2015.
18. **West H & Jin J.** Performance status in cancer patients. *JAMA Onc* 1: 998, 2015.
19. **West H & Jin J.** Transarterial chemoembolization. *JAMA Oncol* 1: 1178, 2015.
20. **West H.** The slippery slope of broadening eligibility and weak endpoints: defending the *oligo* in oligometastatic non-small cell lung cancer. *JAMA Oncol* 1: 1219-1220, 2015..
21. **West H.** Balancing benefit, risk, and time to new cancer therapies. *JAMA Oncol* 2016, 2: 122.
22. **West H & Jin J.** Portacaths. *JAMA Oncol* 2: 152, 2016.
23. Bates G, Taub R, & **West H.** Fertility and cancer treatment. *JAMA Oncol* 2: 284, 20156.
24. **West H.** Young patients with lung cancer – an understudied population. *JAMA Oncol* 2: 321, 2016.
25. Subbiah V & **West HL.** Bone complications in patients with cancer. *JAMA Oncol* 2: 695, 2016.
26. **West H.** No solid evidence, only a hollow argument for universal tumor sequencing; Show me the data. *JAMA Oncol* 2: 717-718, 2016.
27. **West H & Jin J.** Lymph nodes and lymphadenopathy. *JAMA Oncol* 2: 971, 2016.
28. Subbiah V & **West HL.** Jaundice (hyperbilirubinemia) in cancer. *JAMA Oncol* 2: 1236, 2016.
29. **West H.** Can we define and reach precise goals for precision medicine in cancer care? *J Clin Oncol* 34: 3595-3597, 2016.
30. Gupta A & **West H.** Mucositis (or stomatitis). *JAMA Oncol* 2: 1379, 2016.
31. **West H.** Highlights of recent studies of metastatic non-small cell lung cancer. *JAMA Oncol* 3: 159-160, 2017.
32. **West H.** Bringing adjuvant chemotherapy for resected non-small cell lung cancer into real-world practice: Better late than never? *JAMA Oncol* 3: 619, 2017.
33. **West H.** Do the data on scalp cooling for patients with breast cancer warrant broad adoption? *JAMA Oncol* 3: 1147, 2017.
34. Pagel J & **West H.** Chimeric antigen receptor T-cell as cancer therapy. *JAMA Oncol* 3: 1595, 2017.
35. Patel S & **West H.** Febrile neutropenia. *JAMA Oncol* 3: 1751, 2017.
36. **West H.** Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. *Ann Transl Med* 5: 371-379, 2017.
37. **West H.** Complementary and alternative medicine. *JAMA Oncol* 4: 1147, 2018.
38. Gupta A, Wolfe HR, & **West H.** I have neutropenia – what do I need to know? *JAMA Oncol* 4: 1307, 2018.
39. **West H.** Redefining the value proposition of precision oncology: can we integrate genomic testing without overselling it? *JAMA Oncol* 4: 1423-1424, 2018.
40. **West H & Dahlberg S.** Clinical trials, endpoints, and statistics. Measuring and comparing clinical treatments in practice. *JAMA Oncol* 4: 1798, 2018.
41. Gyawali B & **West H.** Plasma vs tissue next-generation sequencing in non-small cell lung cancer – either, both, or neither? *JAMA Oncol* 2018 doi:10.1001/jamaoncol.2018.4304 (online ahead of print).

Book Chapters: 8 Total

1. Mark GP, Schwartz, DH, Hernandez L, **West HL**, & Hoebel BG. Application of brain microdialysis to the study of motivation and conditioning: Measurements of dopamine and serotonin in freely-behaving rats. In: TE Robinson & JP Justice, Eds.: Microdialysis in Neuroscience. Amsterdam: Elsevier Science Publishing, pp. 131-136, 1993.
2. **West HL**, Rebeck GW, Growdon JH, & Hyman BT. Apolipoprotein E4 affects neuropathology but not clinical progression in Alzheimer's disease. In: K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer's disease and Related Disorders. Chichester, UK: John Wiley & Sons, pp. 363-370, 1995.
3. Hyman, BT, Sodhi, P, Harr SD, **West HL**, Simonian NA, Rebeck GW, Mui S, & Isla-Gomez T. The paradox of neurofibrillary tangles and senile plaques in Alzheimer's disease. In: K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer's disease and Related Disorders. Chichester, UK: John Wiley & Sons, pp. 453-460, 1995.
4. Brendel D, **West H**, Hyman S. Hallucinogens. In: D Roberts & L Friedman, Eds., Source Book of Substance Abuse and Addiction. Baltimore, MD: Williams & Wilkins, pp. 217-230, 1995.
5. **West H** & Kelly K. Pleural malignancies and benign neoplasms of the lung. In ME Hanley & C Welsh, Eds., Current Medical Diagnosis and Treatment in Pulmonary Medicine. New York: Lange Medical Books/McGraw Hill, pp. 433-439, 2003.
6. **West H**. Incorporation of novel therapies into the management of locally advanced NSCLC. In R Govindan, Ed., Locally Advanced Non-Small-Cell Lung Cancer. New York: CMP Healthcare Media, pp. 95-105, 2004.
7. **West H** & Garfield D. Bronchioloalveolar Carcinoma: New insights in epidemiology, pathology, and novel strategies. Update chapter for HI Pass, JB Mitchell, DH Johnson, AT Turrisi, & J Minna (Eds.), Lung Cancer: Principles and Practice. Philadelphia: Lippincott, Williams, & Wilkins. Supplement, pp 1-12, 2004.
8. **West H**. Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC), In Lung Cancer, 4th Ed (Roth JA, Cox JD, Hong WK, Chang JY, Blackmon S, & Tsao A, eds.) Wiley Oxford, pp 158-175, 2013.

Published Abstracts: 52 Total

1. **West HL**, Schwartz DH, & Hoebel BG. Local injection of serotonin into the lateral hypothalamus suppresses food intake. *Soc Neurosci Abstr* 15:1281, 1989
2. **West HL**, Robbins TW, & Everitt BE. AMPA-induced cholinergic lesions of the vertical limb of the diagonal band (VDB) impair performance of a conditioned visual discrimination (CVD) task. *Soc Neurosci Abstr* 17: 138, 1991.
3. Hoebel BG, Mark GP, & **West HL**. Conditioned neurotransmitter release as measured by microdialysis. *Clin Neuropharm* 15 Suppl. 1A: 704A, 1992.
4. **West HL**, Rebeck GW, Growdon JH, & Hyman BT. Apolipoprotein E4 affects neuropathology but not clinical progression in Alzheimer's disease. *Neurobiol Aging* 15: S28, 1994.
5. Hyman BT, **West HL**, Harr S, Gomez-Isla T, & Mui S. Quantitative neuropathology in Alzheimer's disease: neuronal loss in high order association cortex parallels dementia. *Neurobiol Aging* 15: S141, 1994.
6. **West HL**, Rebeck GW, Perls T, Sodhi P, Lipsitz L, & Hyman BT. The prevalence of apolipoprotein E4 in the oldest old: connections with Alzheimer's disease. *Neurol* 44: A325, 1994.
7. **West HL**, Taylor LP, & Jacobs AD. Association of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) with progressive sensory polyneuropathy/ataxia: a case report. *Blood* 94 (Suppl 1): 293b, 1999.

8. **West HL**, Livingston RB, Wood DE, Vallieres E, Yaziji H, & Gown A. HER-2/neu (HER2), as assessed by immunohistochemistry (IHC), is rarely expressed in stage I resected non-small cell lung cancer (NSCLC) and does not predict clinical outcome. *J Clin Oncol* 20: 333a (#1327), 2001.
9. Vallieres E, **West HL**, Hunt K, Einck J, & Stelzer K. Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant radiation therapy for malignant pleural mesothelioma: a case series. *J Clin Oncol* 20: 279b (#2867), 2001.
10. **West H**, Livingston R, Wood D, Vallieres E, Giarritta S, Yaziji H, & Gown AM. Overexpression of cyclooxygenase-2 (COX-2) is associated with more aggressive clinical behavior of non-small cell lung cancer. *Lung Cancer* 34 (Suppl 1): 45-46 (#131), 2001.
11. **West H**, Yaziji H, Giarritta S, Livingston RB, Vallieres R, Wood DE, & Gown A. Overexpression of cyclooxygenase-2 (COX-2) is associated with increased aggressiveness of non-small cell lung cancer (NSCLC) tumors. *J Clin Oncol* 2002; 21: 309a (#1235).
12. Miller DL, Vallieres EC, **West H**, Okuno SH, Marks RS. Operative morbidity and mortality after induction chemotherapy and extrapleural pneumonectomy for malignant pleural mesothelioma. *Proc Eur Assoc for Cardiothor Surg* 16 (A#1202), 2002.
13. Franklin WA, Gumerlock PH, Crowley J, Chansky K, **West H**, & Gandara DR. EGFR, HER2, and ERBB pathway activation in bronchioloalveolar carcinoma (BAC): Analysis of SWOG 9714 and lung SPORE tissue samples. *J Clin Oncol* 22: 620 (#2493), 2003.
14. Lau DHM, **West H**, Laptalo L, Geraghty E, Seibert A, Crowley J, & Gandara D. Computer-assisted image analysis of response in bronchioloalveolar carcinoma to ZD1839. *Lung Cancer* 41: S55, 2003.
15. **West HL**, Franklin WA, Gumerlock P, Vance RB, Lau DHM, Chansky K, Crowley J, McCoy J, & Gandara DR. ZD1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG S0126. *Lung Cancer* 41: S56, 2003.
16. **West HL**, Franklin WA, Gumerlock P, Vance RB, Lau DHM, McCoy J, Crowley J, & Gandara DR. Gefitinib (ZD1839) Therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. *J Clin Oncol* 23: 618 (#7014), 2004.
17. Franklin WA, Chansky K, Gumerlock PH, Crowley J, Hirsch FR, **West H**, Crowley JJ, & Gandara DR. Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). *J Clin Oncol* 23: 619 (#7015), 2004.
18. Gold PJ, Refice S, & **West H**. Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors. *J Clin Oncol* 23: 619 (#2120), 2005.
19. Johnson BE, Ma P, **West H**, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery IW, & Heymach JV. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. *J Clin Oncol* 23: 645 (#7102), 2005.
20. Gumerlock PH, Holland WS, Chen H, Franklin WA, Hirsch FR, Mack PC, Davies AM, **West H**, & Gandara DR. Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group trial S0126 of bronchioloalveolar carcinoma (BAC) patients treated with gefitinib. *J Clin Oncol* 23: 623 (#7008), 2005.
21. Hirsch FR, Gandara DR, McCoy J, Crowley J, **West H**, Gumerlock PH, Bunn PA, Franklin WA, & Varella-Garcia M. Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). *J Clin Oncol* 23: 628 (#7030), 2005.
22. **West H**, Belt RJ, Wakelee HA, Bloss LP, Taylor L, Monberg MJ, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. *J Clin Oncol* 23: 645 (#7117), 2005.

23. Hyunh MT, Lehrenbacher L, **West H**, Davies A, Simmons J, Lara P, Yarorkovsky L, Russin M, Gandara DR, & Lau D. A multi-institution phase II trial of irinotecan and carboplatin for extensive or relapsed small cell lung cancer. *J Clin Oncol* 23: 662 (#7169), 2005.
24. Heymach J, **West H**, Kerr R, Prager D, Sandler A, Herbst R, Stewart D, Dimery I, & Johnson B. ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized phase II study. *Lung Cancer* 49 (Suppl 2): S247-248 (A#P-497), 2005.
25. Hirsch FR, Franklin WA, McCoy J, Capuzzo F, Varella-Garcia M, Witta SE, Gumerlock P, **West H**, Gandara DR, & Bunn P.A, Jr. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. *J Clin Oncol* 24: 382 (A#7072), 2006.
26. **West H**, Belt RJ, Wakelee HA, Monberg MJ, Frye LA, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical trial. *J Clin Oncol* 24: 393 (A#7116), 2006.
27. **West H**, Lee S, Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO , Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. *J Clin Oncol* 25: 430s (A#7685), 2007.
28. **West H**, Lee S, Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO , Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. *J Thor Oncol* 2(8) Suppl 4:S334 (A#B1-04), 2007.
29. Green MR, **West H**, Socinski MA, Willey J, Daniels L, Lemke K, Rafferty G, & Iovino L. Management of N3 stage IIIB NSCLC: Changes in US physician behavior following ASCO 2007. *J Clin Oncol* 26: A#7579, 2008.
30. **West H**, Chansky K, Franklin WA, Hirsch FR, Crowley JJ, Lau DH, & Gandara DR. Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. *J Clin Oncol* 26: A#8047, 2008.
31. Hanna NH, Estes D, Arnott J, Marcotte A, Hannah A, Sidor CF, **West H**, Clamon G, & Hoang T. Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 27: A#e19005, 2009.
32. Wakelee H, Gettinger S, Engelman J, Jänne P, **West H**, Subramaniam D, Leach J, Wax M, Yaron Y, & Lara P. A phase 1b/2 study of XL184 (BMS 907351) with & without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). *J Clin Oncol* 28 15s (suppl., A#3017), 2010
33. Green MR, Wozniak AJ, Willey J, Lemke KE, & **West HJ**. Plans of American medical oncologists (AMO) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC). *J Clin Oncol* 28 15s (suppl., A#7568), 2010.
34. **West H**, Moon J, Hirsch F, Mack PC, Wozniak A, Redman M, & Gandara DR. The combination of erlotinib/bevacizumab in never-smokers with advanced lung adenocarcinoma: Southwest Oncology Group (SWOG) trial 0636. *J Thor Oncol* 6 (Suppl 2:S552-553, A#MO-09-03-4), 2011.
35. **West H**, Moon J, Hirsch FR, Mack PC, Wozniak AJ, Lau D, Fehrenbacher L, Bury MJ, Redman MW, & Gandara DR. SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). *J Clin Oncol* 30 (suppl., A#7517), 2012.

36. Mack PC, Moon J, **West H**, Franklin WA, Varella-Garcia M, Wynes MW, Wozniak AJ, Redman MW, Hirsch FR, Gandara DR. Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib & bevacizumab in never-smokers with advanced NSCLC. *J Clin Oncol* 30 (suppl., A#7552), 2012.
37. Gandhi L, Shaw A, Gadgeel SM, Riely G, Cetnar J, **West H**, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter AH, Bordogna W, Balas B, Puig O, Henschel, Ou S-HI. A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an *ALK+* non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). *J Clin Oncol* 33 (suppl; A#8019), 2015.
38. Spigel DR, Reckamp KL, Rizvi NA, Poddubskaya E, **West H**, Eberhardt WEE, Baas P, Antonia SJ, Pluzanski A, Vokes EE, Holgado E, Waterhouse DM, Ready N, Gainor JF, Aren OR, Horn L, Paz-Ares L, Baudelet C, Lestini BJ, Brahmer JR. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). *J Clin Oncol* 33 (suppl; A#8009), 2015.
39. Yu HA, Oxnard GR, Spira AI, Horn L, Weiss J, Feng Y, **West H**, Giaccone G, Evans TL, Kelly RJ, Fleege T, Poondru S, Jie F, Aoyama K, Foley MA, Whitcomb D, Keating AT, Krivoshik AP. Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation-positive NSCLC. *J Clin Oncol* 33 (suppl; A#8083), 2015.
40. Liu SV, Arrawal C, Carter C, Gerber DE, Gitlitz B, Horn L, Solomon B, Stinchcombe T, Villaruz L, **West H**, Kroll S, Pearce T, & Camidge Dr. A phase 2 study of tarloxotinib bromide (TH-4000) in patients with EGFR mutant, T790M-negative, advanced NSCLC progressing on an EGFR TKI. *J Thorac Oncol* 10 (Suppl #2, A#P1.01-084) 2015.
41. Langer CJ, Hirsh V, Amiri K, Ko A, Knoble JL, Johnson ML, Jotte RM, McLeod M, Ong TJ, Page RD, Spigel DR, **West H**. Quality of life (QoL) by response: An interim analysis of patients (pts) with squamous (SCC) NSCLC treated with *nab*-paclitaxel/carboplatin (*nab*-P/C) induction therapy in the phase III ABOUND.sqm study. *J Clin Oncol* 34 (suppl 7S, A#63), 2016.
42. Kim D-W, Tiseo M, Ahn M-J, Reckamp RL, Hansen KH, Kim S-W, Huber RM, **West H**, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares LG, Smit EF, Kim ES, Reichmann WG, Kerstein D, Haluska FG, Camidge DR. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory *ALK+* non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). *J Clin Oncol* 34, (suppl; A#9007), 2016.
43. Liu SV, Aggarwal C, Brzezniak C, Doebele RC, Gerber DE, Gitlitz B, Horn L, Solomon BJ, Stinchcombe T, Villaruz LC, **West H**, Kroll S, Pearce TE, Camidge DR. Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-mutant, T790M-negative NSCLC progression on an EGFR TKI. *J Clin Oncol* 34 (suppl; A#TPS9100), 2016.
44. Yu HA, Spira AI, Horn L, Weiss J, **West H**, Giaccone G, Evans TL, Kelly RJ, Desai BB, Krivoshik A, Fleege TE, Poondru, Jie F, Aoyama K, Whitcomb DA, Keating AT, Oxnard GR. Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer. Interim results from an ongoing phase 1 study. *J Clin Oncol* 34 (suppl; A#9050), 2016.
45. Jotte RM, Socinski MA, Reck M, Papadimitrakopoulou V, West H, Mok T, Sandler A, Mocchi S, Coleman S, Asakawa T, Cappuzzo F. First-line atezolizumab plus chemotherapy in chemotherapy-naïve patients with advanced NSCLC: a phase III clinical program. *J Thorac Oncol* 11 (suppl; A#PS01.53), 2016.
46. **West H**, Nishio M, Dols MC, Saito H, Howland M, Hoang T, Deng T, Sandler A, Socinski MA. Impower132: a phase III clinical trial of 1L atezolizumab plus platinum-based chemotherapy in chemotherapy-naïve advanced non-squamous NSCLC. *J Clin Oncol* 34 (suppl; A#TPS9101), 2017

47. Bazhenova L, Hodgson JG, Langer CJ, Simon GR, Gettinger SN, Ou S-HI, Reckamp KL, **West H**, Chiappori A, Koh HA, Molina JR, Shaw AT, Patel JD, Favaro JP, Haney J, Reichmann W, Kerstein D, Rivera VM, Camidge DR. *J Clin Oncol* 34 (suppl; A#9065), 2017.
48. Cappuzzo F, Reck M, Papdimitrakopoulou V, Jotte R, **West H**, Mok T, Mocchi S, Coleman S, Asakawa T, & Socinski S. First-line atezolizumab plus chemotherapy in chemotherapy-naïve patients with advanced NSCLC: a phase III clinical program. *J Thorac Oncol* 12 (suppl; A#P3.02C-038), 2017.
49. Huber RM, Kim D-W, Ahn M-J, Langer CJ, Tiseo M, **West H**, Groen HJM, Reckamp KL, Hochmair MJ, Leighl NB, Holmskov Hansen K, Gettinger SN, Paz-Ares LG, Kim ES, Smit EF, Kim S-W, Reichmann W, Kerstein D, & Camidge DR. Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status. *J Clin Oncol* 36 (suppl; A#9061), 2018.
50. Pan X, Huang H, Salvatore G, Clarke S, & **West H**. ALKConnect: an anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) patient insights network: *J Thorac Oncol* 13 (suppl; A#P1.15-16), 2018.
51. **West H**. The great oligometastatic debate: locally ablative therapies should be standard treatment for patients with oligometastases. *J Thorac Oncol* 13, 2018 (suppl; A#PC08.01), 2018.
52. Cappuzzo F, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp H-G, Daniel D, McCune S, Mekhail T, Zer A, Kowanetz M, Lin W, Sandler A, & **West H**. IMpower130: progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. *Ann Oncol* 29 (suppl 8; A#LBA53), 2018.

IX. INVITED SEMINARS/LECTURES/FORUMS

- | | |
|-------|---|
| 7/04 | Bronchioloalveolar carcinoma (BAC) and the epidermal growth factor receptor (EGFR) axis. Cancer Research and Biostatistics (CRAB) Lecture Series, Seattle, WA |
| 10/04 | EGFR tyrosine kinase inhibitors in NSCLC. Scripps Oncology Conference. Hilton Head, SC. |
| 6/05 | Examining options for maintenance therapy in non-small cell lung cancer. VA Puget Sound Grand Rounds, Seattle, WA |
| 9/06 | Non-small cell lung cancer: Critical choices for the curable patient. Madigan Army Medical Center, Grand Rounds, McChord, WA |
| 1/07 | Targeted therapeutic strategies in lung cancer. Lung Cancer Affinity Group, Seattle, WA |
| 9/07 | Optimal second-line therapy for recurrent NSCLC. 3 rd Annual Oncology Congress, San Francisco, CA |
| 10/07 | Adjuvant chemotherapy for resected non-small cell lung cancer. National Oncology Summit, Washington, DC |
| 10/07 | Current standards in extensive stage small cell lung cancer. American Society for Therapeutic Radiation and Oncology (ASTRO) Annual Conference, Los Angeles, CA |
| 2/08 | Role of AS 1404 in treatment of non-small cell lung cancer. Targeted Therapies in Lung Cancer Conference, Santa Monica, CA |
| 6/08 | EGFR molecular testing in NSCLC: The argument against routine use (debate). International Lung Cancer Congress. Koloa, HI |
| 8/08 | Personalizing non-small cell lung cancer treatment using histology-based approaches. Hoag Hospital, Newport Beach, CA |
| 11/08 | Sequencing, Timing, and Duration of Therapy. Second Line Therapy and Beyond, CME educational symposium, Chicago, IL |

- 4/09 EGFR inhibitors for the frontline treatment of non-small cell lung cancer. Kaiser Permanente, Walnut Creek, CA
- 6/09 Hsp90 inhibition in lung cancer: Translating from the bench to the clinic. International Lung Cancer Congress, Waikaloa, HI
- 7/09 Talk with the Doctor About Lung Cancer, Gilda's Club, Seattle, WA
- 7/10 Highlights in small cell lung cancer and stage I-III non-small cell lung cancer. Commentary presented at Best of ASCO Conference: Seattle, WA
- 6/11 Learning as if your life depends on it. Patient self-education to improve cancer care. TEDxOverlake: Redmond, WA
- 8/11 Highlights in small cell lung cancer and stage I-III non-small cell lung cancer. Best of ASCO, Seattle, WA
- 11/11 Individualizing first line and maintenance therapy strategies for advanced NSCLC, Nevada Cancer Institute Grand Rounds, Las Vegas, NV
- 2/12 Anti-tumor vaccine strategies in NSCLC. IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 6/12 Physician participation online: Adapting to a new model of interaction between doctors and engaged patients. ASCO Annual Conference: Chicago, IL
- 8/12 Ensuring personalization of care across the continuum of disease and treatment settings: Best practices in the management of advanced NSCLC. UC San Diego Nevada Cancer Institute, Las Vegas, NV
- 10/12 Changes afoot: A new model of interaction between doctors and engaged patients. LIVESTRONG REV Forum, Austin, TX.
- 6/13 The clinical perspective on acquired resistance: Identifying and overcoming barriers. ASCO Annual Conference: Chicago, IL
- 9/13 Personalized approaches in the management of advanced non-small cell lung cancer. Virginia Piper Cancer Center, Scottsdale, AZ
- 11/13 Vaccine strategies: where are we today with active immunity for NSCLC? Personalized Therapies and Best Clinical Practices for Lung Cancer. Los Angeles, CA
- 2/14 Acquired resistance to targeted therapies in advanced non-small cell lung cancer: New strategies and new agents. Scripps Hematology and Oncology Conference, La Jolla, CA
- 4/14 Non-small cell lung cancer: Essential developments in treating metastatic disease, Diablo Society of Health System Pharmacists, Walnut Creek, CA
- 6/14 Right patient, right drug, right time. Expert commentary at Metastatic Non-Small Cell Lung Cancer Oral Abstracts Session, ASCO Annual Conference: Chicago, IL
- 8/14 Highlights in metastatic non-small cell lung cancer from ASCO 2014. Best of ASCO Conference, Seattle, WA
- 11/14 A Closer Look at Personalized Treatment in the Management of Advanced NSCLC; Fall Managed Care Forum, Las Vegas, NV
- 2/15 EGFR + MEK inhibition, IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 2/15 DS-2248, IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 3/15 Transitioning survival from months to years: New developments in advanced NSCLC. Denali Oncology Group Conference, Fairbanks, AK
- 4/15 Social media as an educational and research tool in oncology. Providence Cancer Leadership council. Renton, WA

- 5/15 Biomarkers of acquired resistance: Detecting EGFR T790M in tissue and in blood; Growing Family of EGFR Inhibitors (ASCO CME Symposium), Chicago, IL
- 9/15 Oncology in a digital age: Cancer Care 2.0? Providence Cancer Leadership Council, Renton, WA
- 9/15 Management of Stage I – III NSCLC: MD Anderson Cancer Center Board Review Course, Houston, TX
- 9/15 Meet the experts: squamous cell lung cancer. 16th World Conference on Lung Cancer: Denver, CO
- 9/15 New kinase targets (expert commentary). 16th World Conference on Lung Cancer: Denver, CO
- 3/16 How immunotherapy in lung cancer is changing practice. Rush University Medical Center, Chicago, IL
- 5/16 How immunotherapy in lung cancer is changing practice. City of Hope, Duarte, CA
- 6/16 Highlights of the day: Metastatic non-small cell lung cancer. ASCO Annual Conference: Chicago, IL
- 7/16 Evolution of practice and dissemination of new data in the era of targeted therapy and social media. Best of ASCO Miami, Miami, FL
- 7/16 Advanced NSCLC: Overview of therapeutic options. Lung Cancer Master Class, Dallas, TX
- 10/16 EGFR mutation-positive NSCLC today: New options in a new therapeutic landscape. Personalized Medicine in Lung Cancer Conference, San Francisco, CA
- 11/16 Is there an optimal EGFR TKI? Examining the evidence. Chemotherapy Foundation Symposium, New York, NY
- 2/17 NSCLC overview: Clinical decision-making now and into the future. Lung Cancer Master Class, Dallas, TX
- 2/17 Immunotherapy in NSCLC: Translating trial data into clinical practice, Seattle, WA (national telecast, CME program)
- 2/17 Advanced NSCLC: So many options, how do I choose? PRIMO Annual Conference: Maui, HI
- 2/17 Changing patient/physician dynamics in the era of personalized medicine and social media. PRIMO Annual Conference: Maui, HI
- 2/17 Are we curing patients with immune checkpoint inhibitors? Yes (debate). IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 3/17 What is the optimal duration of immunotherapy for advanced NSCLC? Immune therapies for Cancer Master Class, Dallas, TX
- 4/17 Optimal treatment approaches for first-line and acquired resistance treatment of ALK-positive NSCLC. OncLive State of the Science: Seattle, WA
- 5/17 Choosing therapies for EGFR mutation-positive NSCLC. VA Southern Nevada Hospital, Las Vegas, NV
- 6/17 Immune checkpoint inhibitors in first-line therapy for advanced non-small cell lung cancer. ASCO Symposium on Immunotherapy in NSCLC, Chicago, IL
- 7/17 State of the art molecular diagnosis and targeted therapies in lung cancer, in a new world of social media. Best of ASCO Miami, Miami, FL
- 7/17 Choosing therapies for EGFR mutation-positive NSCLC. Loma Linda, CA
- 9/17 Evolving strategies for previously treated advanced NSCLC. Updates in Medical Oncology, San Francisco.
- 10/17 Immunotherapy: Critical issues in NSCLC management. Immune Therapies for Cancer Master Class, Dallas, TX

- 10/17 New targets and treatments in EGFR mutation-positive acquired resistance. IASLC 18th World Conference on Lung Cancer, Yokohama, Japan.
- 10/17 Immunotherapy for lung cancer: Breaking into a curative role? West Oncology Conference, Memphis, TN
- 11/17 What is the best treatment for advanced non-squamous NSCLC without a driver mutation? Chemotherapy Foundation Symposium, New York, NY
- 11/17 Optimal first line treatment of driver mutation-positive NSCLC: A rapidly evolving landscape. Immunotherapy and Targeted Therapies in Cancer Care, San Francisco, CA
- 1/18 Medical communication 2.0. Physician interaction with the medical and patient community. Pioneers Summit, Austin, TX
- 2/18 First line therapy in advanced NSCLC without a driver mutation: Evolving strategies and emerging options. PRIMO Annual Conference: Maui, HI
- 2/18 Between the motion and the act falls the shadow: the disparity between best evidence and actual clinical practice in cancer care. PRIMO Annual Conference: Maui, HI
- 2/18 Small cell lung cancer: nivolumab, monotherapy and combinations. IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 7/18 This changes everything: Key developments in how oncology practice is evolving. Best of ASCO Miami, Miami, FL, 7/18.
- 8/18 Stage III NSCLC: Where are we now? Medical Oncology Group of Australia Annual Society Meeting, Adelaide, South Australia
- 8/18 Biomarkers in immunotherapy for lung cancer: PD-L1, TMB, and beyond. Medical Oncology Group of Australia Annual Society Meeting, Adelaide, South Australia
- 8/18 ASCO 2018 highlights in metastatic NSCLC. 6th International Conference on Advances in Hematology and Oncology, Coeur d'Alene, ID
- 9/18 The great oligometastatic debate: locally ablative therapies should be standard treatment for patients with oligometastases. World Conference on Lung Cancer, Toronto, ON, Canada
- 10/18 Tumor mutational burden as a clinical tool for advanced NSCLC. Master Class in Lung and Head/Neck Cancer, Dallas, TX
- 10/18 Current standards of care for managing advanced squamous NSCLC. Master Class in Lung and Head/Neck Cancer, Dallas, TX
- 10/18 Emerging options in managing CNS disease in NSCLC: The expanding role of systemic therapies. Personalized Therapies in Lung Cancer, San Francisco, CA
- 11/18 Optimizing treatment strategies in the management of advanced non-small cell lung cancer (NSCLC): Individualized therapy for improved patient outcomes. Fall Managed Care Forum, Las Vegas, NV
- 2/19 TAK-788. IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA.
- 2/19 Case-based peer perspectives on immunotherapy in lung cancer. Santa Monica, CA